Dramatic tumor shrinkage was noted in a recent mutated KRAS lung cancer model when treated with a combination of a dual PI3K/mTOR inhibitor and a MEK (MAP/ERK kinase) inhibitor (Engelman et al., 2008). Here, MTOR is linked to neoplasm.